February 09, 2024
1 min watch
Save
VIDEO: ‘Large uptick’ in use of faricimab for RVO predicted for 2024
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this expert perspective from Hawaiian Eye 2024, Roger A. Goldberg, MD, MBA, discusses what to expect for the treatment of retinal vein occlusion, or RVO, in 2024.
“The update to the faricimab label was somewhat recent, so I think we’ll see a large uptick in the use of that drug in 2024,” Goldberg said. “I believe it’s going to be a longer period of time for aflibercept 8 mg to get approved for RVO, so my expectation for 2024 would be increased utilization of faricimab for RVO.”
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Goldberg reports consulting for AbbVie, Annexon, Apellis, Biogen, Boehringer Ingelheim, EyePoint, Genentech, Outlook Therapeutics, Regeneron and Zeiss; speaking for Apellis, Biogen and Genentech; and serving as an independent research contractor for AffaMed, Alexion, Annexon, Apellis, Boehringer Ingelheim, Cognition, EyePoint, Genentech, Janssen, Neurotech, Novo Nordisk, OcuTerra and Unity Bio.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.